Royalty Pharma
RPRX
335 hedge funds and large institutions have $10.9B invested in Royalty Pharma in 2023 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 143 increasing their positions, 98 reducing their positions, and 42 closing their positions.
472% more call options, than puts
Call options by funds: $37.9M | Put options by funds: $6.62M
46% more repeat investments, than reductions
Existing positions increased: 143 | Existing positions reduced: 98
14% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 42
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
0% more funds holding
Funds holding: 334 → 335 (+1)
0.3% more ownership
Funds ownership: 67.8% → 68.1% (+0.3%)
8% less capital invested
Capital invested by funds: $11.8B → $10.9B (-$928M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$85.4M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$66.7M |
| 3 |
Swedbank
Stockholm,
Sweden
|
+$45.1M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$44.3M |
| 5 |
Goldman Sachs
New York
|
+$40.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$153M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$124M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$80.5M |
| 4 |
Morgan Stanley
New York
|
-$70.3M |
| 5 |
HSBC Holdings
London,
United Kingdom
|
-$27.8M |
RPRX Hedge Fund Activity: Q1 2023 in Review
335 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q1 2023, worth a combined $10.9B — down 7.9% from $11.8B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new RPRX positions and 42 closed out — a net gain of 6 holders — while 143 added to existing stakes and 98 trimmed.
The largest buyer was Vanguard Group, adding an estimated $85.4M. The largest seller was Fidelity Investments, cutting an estimated $153M.
- 335 institutional investors held Royalty Pharma (RPRX) as of Q1 2023, up from 334 in Q4 2022.
- Funds reported $10.9B of Royalty Pharma stock for Q1 2023, down 7.9% quarter-over-quarter.
- 48 funds opened new Royalty Pharma positions in Q1 2023 and 42 closed out, a net change of +6 holders.
- The largest Royalty Pharma buyer in Q1 2023 was Vanguard Group, an estimated $85.4M added.
- The largest Royalty Pharma seller in Q1 2023 was Fidelity Investments, an estimated $153M sold.
Based on aggregated 13F filings for Q1 2023.